BioCentury | Aug 19, 2020

Momenta’s shift to innovative pipeline pays off with $6.5B J&J takeout

...drugs include Remicade infliximab, Simponi golimumab, Stelara ustekinumab and Tremfya guselkumab. U.S. patent exclusivity for Stelara...
BioCentury | Jul 2, 2020
Product Development

July 1 Quick Takes: Amgen gains on court win; plus Hua, J&J, argenx, Seattle Genetics-Genmab, Interprotein

...The pharma also discontinued the Phase III LOTUS study in systemic lupus erythematosus after Stelara ustekinumab...
BioCentury | Apr 14, 2020

COVID-19 pushes J&J to slash guidance; vaccine initiative on track

...start of the year. J&J doesn’t break out its guidance by segments. Autoimmune drug Stelara ustekinumab...
BioCentury | Nov 1, 2019
Company News

Skyrizi launch beats expectations again as AbbVie looks to post-Humira future

...p19 subunit of IL-23, and has shown significantly greater efficacy than approved IL-23 inhibitor Stelara ustekinumab...
BioCentury | Oct 21, 2019
Company News

Oct. 21 Company Quick Takes: Vertex's triplet gains FDA approval; plus Bavarian Nordic-GSK, Farxiga, Ultomiris, Stelara

...Review That Could Shorten Soliris’ Exclusivity” ). Stelara approved for ulcerative colitis FDA approved Stelara ustekinumab...
...moderate to severe active ulcerative colitis in adults. The Johnson & Johnson (NYSE:JNJ) unit said Stelara...
BioCentury | Aug 2, 2019
Financial News

Aug. 2 Financial Quick Takes: Rakuten Medical bags another $100M; plus CGeneTech, Zecen, Qyuns and more

...a series B round also backed by Hefu Ruitai and Triwise Capital. Its tocilizumab and ustekinumab...
BioCentury | Jul 27, 2019
Company News

Vitrakvi set to become EU’s first tissue-agnostic cancer drug

...NASDAQ:ALXN) for neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-AQP4 antibody positive; Stelara ustekinumab...
BioCentury | Apr 24, 2019
Company News

AbbVie successor to Humira in psoriasis gains FDA approval

...led to clear or almost clear skin in 88% and 84% of patients, respectively. Stelara ustekinumab...
BioCentury | Feb 21, 2019
Translation in Brief

Bugging inflammation in lung cancer

...the collaboration might study the inflammatory targets identified in his team's paper. J&J markets Stelara ustekinumab...
BioCentury | Jan 26, 2019
Product Development

Target wide, test narrow in lupus

...both JAK-1 and JAK-2 and is marketed for rheumatoid arthritis (RA). Johnson & Johnson’s Stelara ustekinumab...
...IL-23) receptors, enabling it to inhibit Th1 and Th17 T cells. Both the Olumiant and Stelara...
Items per page:
1 - 10 of 196